A strategy to reduce cardiovascular disease by more than 80%

By N. Wald, M. Law. British medical journal, 2003

1,665 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Prognosis and prognostic research: application and impact of prognostic models in clinical practice (2009, background): “Changes over time may even lead to the situation that prognostic models are no longer used to estimate outcome risks and to influence patient management. For example, the suggestion that everyone older than 55 is given a “polypill” to reduce the risk of cardiovascular diseases”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “55 years of age.(493) A recent systematic review and meta-analysis(485) summarizes nine randomized trials (n 1⁄4 7047) on FDCs, largely conducted in higher-risk populations and primarily designed to evaluate changes in CV risk factors and adherence.”
Exercise is the real polypill. (2013, background): “Wald and Law first described a combination pill for CVD prevention (498), which they called a “polypill” (499).”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, neutral): “advocated.(78) However, exposure to common risk factors also increases with age, and between one-third and one-half of the age differences (between 25–49 vs.”